Molecular Targeting Technologies, Inc.

Website Links

Description

MTTI is a privately held US-based Biotechnology Company developing novel medical imaging products for the diagnosis of cardiovascular disease and cancer. MTTI is also developing a novel recombinant rabies vaccine for the oral vaccination of wildlife, as well as human anti-rabies monoclonal antibodies for post-exposure prophylaxis of rabies in China. The company has recently acquired rights to a unique fusion protein technology for the development of potent vaccines. This technology will initially be targeted to the development of Anthrax and Botulinum Vaccine.

Products & services

Similar companies nearby